nct_id,brief_title,page_rank_score_brief_title,page_rank_score_brief_title_summary_combined
NCT01746771,A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer,0.0017174425625474403,0.0016990688401353315
NCT01748851,XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC),0.002982652156242631,0.0018659651754265962
NCT01727908,Screening for Familial Gastric Cancer in First Degree Relatives,0.001264259994621804,0.0014009170028908492
NCT01747551,FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,0.002143415849958924,0.002041936946854822
NCT01704664,"Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients",0.0014618685015375275,0.0010356340486080175
NCT01736410,A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer,0.0017578009002091944,0.0019440961930522315
NCT01795027,Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer,0.001564873433608882,0.0017389069727812131
NCT01779583,"Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients (""EXO-PPP Study"")",0.0019538576095652085,0.0018301513551070465
NCT01751880,"Safety, Feasibility and Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Pilot Study",0.0016044961471780139,0.001694514742304164
NCT01719549,Dovitinib for Gastric Cancer With FGFR2 Amplification,0.0015340110040785804,0.0017206522951446126
NCT01743365,Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer,0.0015753465110301063,0.0019026778748924217
NCT01743469,"A Study With Tasquinimod Treating Patients in Four Independent Cohorts of Hepatocellular, Ovarian, Renal Cell and Gastric Cancers",0.0015454309065448073,0.0015400609983108825
NCT01756183,Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer,0.0015740296147519874,0.002323799493540198
NCT01716546,"Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer",0.0016405159428820296,0.0016838535113662507
NCT01715233,"A Phase II Study Investigating Checkpoint With Forkhead and Ring Finger Domains (CHFR) Methylation Status In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer",0.0016871634583489946,0.0017176233955722025
NCT01775514,"A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics",0.0013763659027797982,0.001371565790696224
NCT01757366,Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer,0.0016862812801568417,0.0022012255024099884
NCT01714622,Prospective Cohort Study for Analyzing the Effect of Gastric Cancer Surgery to the Metabolic Syndrome and Insulin Resistance,0.00146827254739747,0.001551824491214525
NCT01742806,Clinical Study for the Impact of Bio-absorbable Felt (NEOVEIL®) With Fibrin Sealant on Removal of Drainage Tube After Minimally Invasive Gastrectomy for Gastric Cancer,0.0013384697458183673,0.0014010397330380209
NCT01718626,Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric Cancer,0.0018010968174478068,0.0017124192152120727
NCT01774266,Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer,0.0011442441593698858,0.0007473886882758617
NCT01774786,A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,0.0015729831258418658,0.0017786069731021074
NCT01783951,Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer,0.0023756891456610764,0.0022808833065676216
NCT01787539,The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer,0.001722594015139177,0.001437788737618529
NCT01702558,A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC),0.001787774409413138,0.0015430616989886407
NCT02890511,"A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer",0.0019264394886476456,0.0019769331108334186
NCT02855788,Metronomic Chemotherapy in Advanced Gastric Cancer,0.0020932244670805477,0.002033871930490754
NCT02817425,A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer,0.0017184167868346467,0.0019243316033293663
NCT02887612,ctDNA for Prediction of Relapse in Gastric Cancer,0.0021501866337910332,0.0010462669787931404
NCT02800005,Effect of Obesity on Surgical Outcomes and Survival for Gastric Cancer,0.0016401951841179849,0.0011737849911895991
NCT02848066,Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker,0.0011056024636903906,0.0015573679809744313
NCT02845986,Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer,0.0017118822756772073,0.0017905108085169194
NCT02867839,Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer,0.0016168830578067628,0.0021308198642198527
NCT02852096,Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks,0.0011039485535664305,0.0010462992678734444
NCT02873520,Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer,0.0016434621257531662,0.001267911730998742
NCT02843412,The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using Immunohistochemistry,0.0013082000071217444,0.001269336520112472
NCT02815150,Safety of 250ml Preoperative Carbohydrate Drink in Gastric Cancer Patients,0.0020334058537350786,0.0016923039208212298
NCT02805829,Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer,0.0013700864207534368,0.0015207381839168759
NCT02872116,Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer,0.0014120141136725268,0.0016178840806652277
NCT02862561,Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer,0.0016434621257531662,0.0013015823162441753
NCT03104283,Apatinib for the Elderly Advanced Gastric Cancer,0.0021379072804092445,0.002616082934642505
NCT01579578,Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer,0.0015634299915675966,0.0019095510815574262
NCT01528501,Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008),0.004083180949620297,0.0012087371032961213
NCT01528059,Roux-en-Y Versus Billroth II Reconstruction After Subtotal Gastrectomy in Gastric Cancer Comorbid With Type II Diabetes,0.0010994440318956367,0.0012222070009301415
NCT01517009,"A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer",0.0015566386064915579,0.0017274274411615297
NCT01549756,Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers,0.0021504537044770245,0.0008945496879610547
NCT01514110,Gastric Cancer RAD001 Study,0.002722476534486823,0.00234531171140022
NCT01514045,The Gastric Cancer Foundation: A Gastric Cancer Registry,0.0015478337633651556,0.0010141599386586544
NCT01542294,SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer,0.0022072861289780814,0.0016505739474259463
NCT01515748,Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer,0.0016666509287870525,0.0015724150959629526
NCT01583361,SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer,0.001299504936247192,0.0014788375698729264
NCT01567618,Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer,0.001595488639827459,0.0018833881724858925
NCT01525771,Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer,0.0019357426298284338,0.0026169073124848972
NCT01573468,Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer,0.001314094166111777,0.0021179505304390845
NCT01558947,Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer,0.0019482146184648913,0.002615026657418074
NCT01531452,The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer,0.0017749062267823567,0.002844702130145898
NCT01598077,"A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer",0.0014107385040315525,0.0011699706632545355
NCT01503983,"Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive",0.0014241166342010751,0.0017599402644748532
NCT01503372,FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer,0.0018072726837940842,0.0020340348454562797
NCT01512745,Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer,0.0018792351907751484,0.0018233416327794244
NCT01516944,Perioperative Chemotherapy for Potentially Resectable Gastric Cancer,0.0024111686619753612,0.001263347017355358
NCT02202759,A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction,0.0017639473798057809,0.002007049731213112
NCT02289547,Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer,0.0020802234282410854,0.0016345169248602304
NCT02289183,Prospective Study on Modified Delta-shaped Gastroduodenostomy in Totally Laparoscopic Surgery for Distal Gastric Cancer,0.0013352807976338124,0.0014473254872147158
NCT02289378,"Dose-dense Biweekly Docetaxel, Oxaliplatin and 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer",0.0016052601386498742,0.0018397047685513503
NCT02274376,Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer,0.0016874526211788545,0.0015369607821741705
NCT02216955,Nutrition and Lifestyle Study Cohort of Gastric Cancer in China,0.0019219574127071078,0.001125197188191288
NCT02291211,S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis,0.0012249616700558174,0.0015133931071618376
NCT02251951,Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer,0.001662067314958071,0.0018841428254242991
NCT02209441,Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer,0.0019873559701694835,0.0018639221622177814
NCT02272894,A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer,0.0014654619231159185,0.0014549287928533646
NCT02215837,Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer,0.0014428807482041557,0.002166350435622864
NCT02219854,Single-center Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer,0.001668470217396564,0.0015306869676238795
NCT02204306,Genotype Guided Chemotherapy in Gastric Cancer Patients,0.0015788127482446249,0.001649757013005494
NCT02226380,FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer,0.0018709037252867245,0.0021651211854678424
NCT02252913,A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer,0.0019387074761121588,0.001898261520347866
NCT02229045,Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer,0.0016544997115675523,0.0017719340468674361
NCT02233712,"Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.",0.0016377448150961722,0.0015244003907557942
NCT02269904,Fluorouracil Implants Used for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer.,0.001273513118965328,0.0015859543734475792
NCT02296658,A Phase II Study of Postoperative S-1-Based Chemoradiotherapy in Gastric Cancer,0.0019487914819426902,0.0016519571454286775
NCT02248519,Laparoscopic Versus Open Gastrectomy for Gastric Cancer,0.0016725654159577008,0.0012682446113741076
NCT02240212,Study of Afuresertib Combined With Paclitaxel in Gastric Cancer,0.001602484592098681,0.0014082131225681852
NCT02240524,Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer,0.0021876767515830384,0.0021709299346229474
NCT02205008,Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer,0.001165939677349755,0.0015060528740595564
NCT02205463,"KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer",0.0014402038778759312,0.0018896372285509856
NCT02298010,Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial,0.0011766681023060487,0.0008929091956722477
NCT02287168,Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients,0.0014255623707470817,0.0012236672009408934
NCT00591045,"Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer",0.001801245616117076,0.001801557726214465
NCT00580359,S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer,0.0016506141109915696,0.0016912382538838637
NCT00587145,Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer,0.002145455690804673,0.0020354057828467736
NCT00526669,Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib,0.001625205179644638,0.0016019535983654901
NCT00598546,Quality of Life Among Long-Term Survivors of Resected Gastric Cancer,0.0012795725689785532,0.0012614173355723927
NCT00595985,Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer,0.0018221598307106828,0.0024011983970121673
NCT00595972,Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer,0.0018467844446840847,0.0018728367317549042
NCT00565370,Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC),0.001876152121744933,0.0011305124858116728
NCT00596401,The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer,0.0015385747506004477,0.0011695340065860675
NCT00533533,A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer,0.0019479601558706956,0.0020946827332093184
NCT00553696,Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer,0.001673320876152972,0.0022082963745882226
NCT00511446,"Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer",0.0017015914001185714,0.0017278138493129036
NCT00525005,"Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer",0.001838383863474416,0.002362519043131458
NCT00519324,Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer,0.00207764911796506,0.0021251012598375234
NCT00555672,Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer,0.002013763321780478,0.0019063126426473126
NCT00555620,Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer,0.002083343703752929,0.001928829295384655
NCT00524186,"Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer",0.0017139329720237452,0.0015766906383669222
NCT00568529,Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer,0.0015450341994338933,0.001896744633037317
NCT00568971,Study of Weekly DCF to Treat Advanced Gastric Cancer,0.002483563305751775,0.002469042395230675
NCT00512304,Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE),0.0013771515647731393,0.0013936679477486494
NCT00512681,"A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer",0.001512850607251177,0.0018444348471864831
NCT00548548,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,0.002119894717623115,0.0020375355665913013
NCT00514020,"Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer",0.0015473743952644562,0.0016417332210719698
NCT02704299,"The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.",0.0017753810565668668,0.0019075414849764082
NCT02799420,Role of Probe-based Confocal Laser Endomicroscopy Targeted Biopsy in the Molecular Study of Undifferentiated Gastric Cancer,0.0012852663543571217,0.001275627350507112
NCT02736552,"Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.",0.001511844814649858,0.0016498038610137141
NCT02748551,A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer,0.001631761405511068,0.0018313348842432452
NCT02746796,Study of ONO-4538 in Gastric Cancer,0.002722476534486823,0.0017461458041065855
NCT02732483,Role of Hemostatic Powder (Endo-clotTM) in Success and Prevention of Bleeding Within Gastric Cancer Patients With Bleeding,0.0013431558884338648,0.0011992650645468782
NCT02781285,Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score,0.0016740919495132679,0.0016236526088930674
NCT02720926,Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer,0.0017226508427781691,0.0017393898538485668
NCT02725125,Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer,0.002722476534486823,0.0015613597182300668
NCT02726399,Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,0.0015002910136879455,0.001864007218261315
NCT02776527,A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy,0.001793026427876936,0.00186902852488271
NCT02777801,Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers,0.0013368603140082775,0.0010831207631181795
NCT02782949,Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia,0.001459527664838552,0.0015258044762692666
NCT02792881,The Safety and Feasibility of Laparoscopic Total Gastrectomy for Remnant Gastric Cancer,0.0013681567086106445,0.0017700300611864085
NCT02711969,"A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment",0.0017426544454629592,0.00184746281247073
NCT02764268,Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer,0.0016571104190836628,0.0020264333092951657
NCT02745509,Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (EIPL),0.001562634822078423,0.0015535109653558375
NCT02795988,A Study of IMU-131 Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Advanced Cancer of the Stomach,0.0020541688699333917,0.002181393720323
NCT03092518,Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology,0.0011610720220158017,0.0014990921610223396
NCT03049345,Gastric Cancer Sentinel Lymph Node Mapping,0.002143415849958924,0.0014140484504967597
NCT03026881,A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients,0.0016611385468920663,0.0017007815988300417
NCT03006705,Study of Adjuvant ONO-4538 With Resected Gastric Cancer,0.00193344583709404,0.0016593318354453843
NCT03006263,Randomized Controlled Trials on Clinical Outcomes of Totally Laparoscopic Versus Laparoscopy Assisted Total Gastrectomy for Gastric Cancer,0.0011830888291831647,0.0014653281832510067
NCT03007446,The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer,0.0017170000055735475,0.0019030372333240855
NCT03001726,Gastrectomy Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric Cancer With a Single Non-curable Factor,0.0015899996423147703,0.0016703816646043098
NCT03023436,Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis,0.0012927934896757001,0.00209381442118874
NCT03081143,"Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy",0.0018925164833015272,0.0016663028280997781
NCT03015675,IV Ascorbic Acid in Advanced Gastric Cancer,0.0020932244670805477,0.001540374002220998
NCT03015298,Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer,0.0014700113325889555,0.0018264998700752368
NCT03061162,Pulsed Low Dose Rate Radiation Therapy for Gastric Cancer Patients With Peritoneal Metastasis,0.001376303760034199,0.0015189495870335768
NCT03061370,Sarcopenia and Visceral Obesity in Esophageal and Gastric Cancer,0.0015317615646111506,0.0013068597999040604
NCT03043183,Enhanced Recovery After Surgery(ERAS) for Gastric Cancer and Perioperative Nutritional Status,0.0015362895515354219,0.0012453788593929666
NCT03030404,Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer,0.0015638460467030117,0.0011205234383531814
NCT03025152,Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Radical Gastrectomy for Gastric Cancer,0.001419606033626516,0.0013511487891238896
NCT03042611,Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer,0.0014963426151781186,0.0019481860738760695
NCT03067792,FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer,0.0017695852831547745,0.0019650246919455153
NCT03067012,Nutritional Safety and Metabolic Benefits of Oncometabolic Surgery for Obese Gastric Cancer Patients,0.001438569746102821,0.0014805047561485172
NCT03076567,Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer,0.001279395908313005,0.001163672926789359
NCT03098758,Molecular Analysis in Peritoneal Washing Citology for Locally Advanced Gastric Cancer,0.0017130088483594702,0.0013534230308038953
NCT00296322,Trial of Adjuvant Chemotherapy for Gastric Cancer,0.0022072861289780814,0.0015799724405506446
NCT00296335,Trial of Adjuvant Chemotherapy for Gastric Cancer,0.0022072861289780814,0.002009804052731865
NCT00275951,Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer,0.0018247816090537006,0.00180016852580924
NCT00252161,A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer,0.0012524791946500187,0.0017831955024186059
NCT00263354,Oxaliplatin in Gastric Cancer,0.002283717300228195,0.001309850560509529
NCT00260884,Phase III Study OF the Gastric Surgery on Advanced Stage Gastric Cancer,0.0017358802448409533,0.0017297364462464859
NCT00209638,Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer,0.0021155226762343653,0.0022794283829120723
NCT00209664,Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer,0.0021155226762343653,0.0022794283829120723
NCT00216034,Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK,0.0014206097069929076,0.001312339548125165
NCT00215644,MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer),0.0016803339343036347,0.0018877410114260759
NCT00201747,Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer,0.0018278853931648048,0.0014831201833799424
NCT00237900,Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer,0.0013383933536529886,0.001209118502177119
NCT00290966,Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer,0.001775908928045354,0.001654445996740134
NCT00202969,"Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer",0.0020373473835309163,0.0017667448533153995
NCT00226811,An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy,0.0021646200155630187,0.0016989293262372968
NCT00270543,An Effective and Well-Tolerated Regimen of Docetaxel Plus High-Dose 5-Fluorouracil and Leucovorin(HDFL)to Treat Inoperable Advanced or Metastatic Gastric Cancer,0.0015818619701738804,0.0016544366586399987
NCT00287768,Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer,0.002068565934842691,0.00193979815557952
NCT02366819,Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer,0.0016812390137050206,0.0018872398442171688
NCT02334332,Educational Brochure in Preparing Patients With Gastric Cancer and Their Caregivers for Recovery After Surgery,0.0014391538378673123,0.0013410745745330434
NCT02380131,Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis,0.0012774753646981449,0.001268986059296652
NCT02305043,Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer,0.0011892221423281289,0.00154917324756798
NCT02322593,Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer,0.002073052832024465,0.0025956494778040383
NCT02359058,A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer,0.001995267089882409,0.0020201259602165744
NCT02317471,Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96,0.0010786866893962444,0.0017037669139958348
NCT02378389,Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer,0.0019878346293251666,0.0019074630110945362
NCT02381847,Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients,0.0021318619099992436,0.0019534393495637572
NCT02375997,Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer,0.0014113572464793953,0.0015175726934405498
NCT02365896,Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer,0.0015042338251436108,0.0010884756631461838
NCT02338518,Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients,0.0014899455799048857,0.001765209041547534
NCT02327481,Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer,0.0011824643744989816,0.0017781424361623535
NCT02395640,The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer,0.0018260066695005197,0.0023348426531980913
NCT02302794,A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery,0.0012554212338576978,0.0012674924257031798
NCT02333721,Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric Cancer,0.0017118822756772073,0.0018546279574718693
NCT02325323,Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia,0.0014578463442311662,0.0013467111784803243
NCT02325453,"Robotic, Laparoscopic and Open Surgery for Gastric Cancer Compared on Surgical, Clinical and Oncological Outcomes",0.0012690725009043464,0.0013493864663230552
NCT02314117,A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,0.001609339211194442,0.0018109694963185112
NCT02356276,Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer,0.0022419040499458056,0.0020799310942818177
NCT01388790,Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer,0.0014512945252894629,0.0010442477370437458
NCT01379482,Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer,0.001147206269865805,0.0013922099871238741
NCT01336062,Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients,0.002213566916693989,0.0015371770493451198
NCT01341756,Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial,0.0017059325838331496,0.0014362570220241332
NCT01331928,Sequential Chemotherapy With Xelox Follows by TX to Treat Gastric Cancer,0.0024111686619753612,0.002015923614129053
NCT01381913,Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer,0.001752272281019102,0.0015135220612694433
NCT01355302,E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer,0.0019259310665838635,0.0019342434164490408
NCT01359397,"Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer",0.001925309603462653,0.0024487123050645682
NCT01366586,Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7-Ag,0.0015363408326091379,0.0018251561022860309
NCT01348009,Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer,0.0016612413441729986,0.0017312970854791122
NCT01338948,Image-guided Minimally Invasive Robotic Surgery Using Preoperative CT Scan for Gastric Cancer Patients,0.0014005041750371936,0.0014790404715902743
NCT01305993,Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer,0.0019519803102696859,0.0022723584320602295
NCT01345773,Incidence of Venous Thromboembolism Following Surgery in Patients With Gastric Cancer,0.0017246953067751546,0.001638846547411618
NCT01364493,"A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer",0.001971628255847605,0.0021205055260536047
NCT01309256,Multi-institutional Study on the Assessment of Robotic Surgery for Gastric Cancer,0.001385674796431556,0.0012133107380125341
NCT01375738,Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With Diabetes Mellitus,0.0013781745368934555,0.0014209717808248148
NCT00887822,A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer,0.0017823115209148774,0.0018130601109256038
NCT00845611,Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer,0.0017555666085748499,0.0018632656244785115
NCT00821990,Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer,0.0018145759151976884,0.0016238130420565284
NCT00857246,Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer,0.0011618443900435883,0.0014640917346278603
NCT00842491,Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer,0.0018210485590694778,0.0018910991074349514
NCT00842244,Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer,0.002035824716016128,0.0019120714254901498
NCT00854854,Efficacy Study of TKcell in Advanced Gastric Cancer,0.002483563305751775,0.0031703095507185416
NCT00858338,Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer,0.0015170627419181968,0.002016110906639793
NCT00851305,Detection of Early Gastric Cancers Using Confocal Laser Endomicroscopy,0.0015410285580018028,0.0020331888645097377
NCT00879333,Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC),0.0018365558100019463,0.002331297353121184
NCT01642953,Early Recovery After Gastric Cancer Surgery,0.0016424614424006847,0.0012888993850532038
NCT01650766,Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers,0.0018633185256460203,0.002074094512115719
NCT01630083,Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer,0.0016319777375641681,0.00123582621291003
NCT01657175,Quality of Life After Oesophageal or Gastric Cancer Surgery,0.0016469446799282402,0.0013600987348141788
NCT01633203,Observational Study of Perioperative Chemotherapy in Gastric Cancer,0.0017096890453540765,0.0016489224891362271
NCT01627119,The Functional and Clinicopathological Roles and Therapeutic Implication of Connective Tissue Growth Factor in Peritoneal Metastasis of Gastric Cancer,0.0011666537689788159,0.0015913311196951907
NCT01602406,Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,0.0017421719690295216,0.0014975686608876652
NCT01664494,"An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer",0.0020197179673044022,0.0018275398056268684
NCT01641939,A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer,0.0016618184636659817,0.0017936964262371714
NCT01641783,Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients,0.0021162380953923783,0.0019455913312545312
NCT01618474,Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients,0.0016858055725003905,0.0014696957702523394
NCT01613950,PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer,0.0018142492431869421,0.0017679644415985068
NCT01665274,Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer,0.0017629660260105931,0.0018731563993422953
NCT01614522,A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2,0.0014574598171526415,0.0015416813115178285
NCT01671449,S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer,0.0016701399449383506,0.0019627902191510236
NCT01671774,Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer,0.0012018546884733168,0.0010294866247923216
NCT01611506,"Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer",0.001503000340732297,0.0014943045391482973
NCT01625702,Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer,0.0017719682244107316,0.0014226866380106578
NCT01609309,Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01),0.0017126172558422717,0.001587978283689946
NCT01637350,Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes,0.0011381117238033803,0.0007553218802697327
NCT01674959,Postoperative IMRT Combined With Capecitabine for Advanced Gastric Cancer Patients,0.002157563332392145,0.0018523604519029393
NCT01683864,Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer,0.0011618067541675054,0.0019329397671958048
NCT01679054,Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong,0.0023647975024357927,0.0017134471377224464
NCT01042782,Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction,0.0019305428744373519,0.0018346396000099136
NCT01099527,A Trial of RAD001/Capecitabine in Refractory Gastric Cancer,0.004083180949620297,0.0019069088029957076
NCT01099085,Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients,0.0018955012448215506,0.001921898841081948
NCT01090505,Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer,0.0018485665749919556,0.0021750170301448337
NCT01043835,Comparison of Laparoscopic Versus Open Gastrectomy for Advanced Gastric Cancer:A Prospective Randomized Trial,0.0015341489953303812,0.002116444668577755
NCT01095120,Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer,0.0019272017379447024,0.0021900973808949937
NCT01041404,ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer,0.0020417149110070645,0.0021722352498686477
NCT01065688,A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer,0.0013525667135436041,0.0016359420834106393
NCT01084330,Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer,0.0020932244670805477,0.0018268673493514666
NCT01070290,A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen,0.0021525772071449728,0.002333800835120043
NCT01047618,Venous Thromboembolism in Advanced Gastric Cancer Patients,0.002074275950522476,0.0016019882111466916
NCT01002443,Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer,0.0017267259543042384,0.0014753574984275862
NCT01088204,Feasibility Study of Laparoscopy-assisted D2 Distal Gastrectomy to Treat Advanced Gastric Cancer,0.0015226088562434442,0.0018090875264209058
NCT01049620,RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer,0.001878722228124682,0.0020804960872596004
NCT01020630,Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI,0.0020831660490268178,0.0016939274012310415
NCT01063517,Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients,0.0017489435144560795,0.0016131127502542046
NCT02404753,A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy,0.001615577406317971,0.0019712196781581323
NCT02401971,Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer,0.0015544778579605996,0.0014175992369224806
NCT02425930,The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer,0.0018252388139030201,0.002278250975803319
NCT02442362,TOF Versus SOX in Metastatic Gastric Cancer,0.002431217704575302,0.0019219513485392143
NCT02423278,The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer,0.0021843669617194897,0.0015862179588143474
NCT02431078,The Expression of ZEB1 in CTCs Associated With Metastasis and Recurrence for Gastric Cancer,0.0012937654604309443,0.0017157920676828227
NCT02454647,"Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients",0.0017933808962409506,0.0019466742502983673
NCT02489214,Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer,0.001725687740481563,0.0016004794731543763
NCT02415023,A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer,0.0017426719674893025,0.0020788800235509042
NCT02450032,Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer,0.0017051757981343908,0.0023200845141044383
NCT02490111,Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer,0.0014371495885894708,0.0017388145228925472
NCT02426034,Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer,0.0018792351907751484,0.001833458524031981
NCT02485015,The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer,0.0020121771253457446,0.0025361561868503476
NCT02409199,A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer,0.002023091830955838,0.0020544711256080686
NCT02464215,Effect of Laparoscopy-Assisted Distal Gastrectomy for Locally Advanced Gastric Cancer,0.0016158002931847303,0.0020776450276131504
NCT00165048,Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial,0.0013377407353717162,0.0013587994889078447
NCT00165594,A Study of E7070 in Patients With Gastric Cancer,0.0019441797839881037,0.0015629349502801857
NCT00154778,"Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric Cancer",0.002086080123075953,0.0022098932625930273
NCT00154726,Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers,0.0018796911770918925,0.0017319900510581589
NCT00142350,A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer,0.0017788404861889253,0.0017970471598404473
NCT00142038,Docetaxel and Capecitabine in Advanced Gastric Cancer,0.001850440121573761,0.001895322077084672
NCT00166881,Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin,0.001217949873450157,0.001762836034782373
NCT00149279,A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer,0.0011720770457324943,0.0015471024199365418
NCT00149266,Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502),0.0012304252608112396,0.001372861662968754
NCT00149201,A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis,0.0014619654003574685,0.002086266620905488
NCT00103103,"Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer",0.0014982856478842396,0.0015291637326671327
NCT00103324,S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer,0.00195465094969491,0.0016841791012772698
NCT00155883,Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer,0.0015637636336878586,0.0015682580973226162
NCT00130689,Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer,0.001459253831908227,0.0014617605440359865
NCT00123318,A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer,0.0012836632413476931,0.0018163361976189212
NCT00147147,Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2),0.0012827021452033532,0.0014242989614810444
NCT00182611,S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer,0.0016088773632020714,0.0015481056615680225
NCT00144378,Irinotecan Versus Only Best Supportive Care for Gastric Cancer,0.0015875520883711501,0.001257860531345286
NCT00150670,Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer,0.0017943092752072524,0.0023667178725558595
NCT00188266,Study of Adjuvant Radiochemotherapy for Gastric Cancer,0.0019242794691864237,0.0020324155421889926
NCT00172627,Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer,0.0015362284228135328,0.0015525863470221125
NCT00152217,Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC),0.0022072861289780814,0.0016863738263656958
NCT00164892,Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial,0.0016542648508143308,0.00170452161901549
NCT00134095,S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer,0.0019265381796321251,0.0017091635365526034
NCT02139605,"""Phase III Randomized Trial Comparing D2 vs D3 Lymphadenectomy With Gastric Cancer Following Neoadjuvant Chemotherapy",0.001323368994784029,0.0017004079819938531
NCT02140034,Extensive Peritoneal Lavage After Curative Gastrectomy for Gastric Cancer: A Randomised Controlled Trial,0.0013355325170603478,0.0013522384724963614
NCT02163291,Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer,0.0019155138325623183,0.001798425658174899
NCT02123407,Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer,0.001675234891048351,0.0013850389238834941
NCT02172690,Laparoscopic Staging for Locally Advanced Gastric Cancer in Chinese Patients,0.0021207564238225857,0.0019527386314504673
NCT02144727,A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer,0.0014950503982932982,0.0014134352299800916
NCT02192983,A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer.,0.0014301944047660704,0.001936010937981499
NCT02120885,"An Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Phase III, Prospective Randomized Controlled Trial",0.0013905149140124222,0.0010783818015239039
NCT02158988,Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis,0.0015432286512354772,0.0019378676965336704
NCT02179463,Compare Different Response Evaluations to Neoadjuvant Chemotherapy for Gastric Cancer,0.0013088472372579938,0.001583375896351263
NCT02184910,"Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea",0.0010738354023036704,0.0007823860333549133
NCT02142322,Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer,0.0029826521562426453,0.002263837360737968
NCT02137343,A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer,0.0016475057069746427,0.0016330853752656185
NCT02198898,Anti-adhesion Effect of GUARDIX-SGⓇ in Gastric Cancer Surgery,0.0016379158631853112,0.0020906860939305535
NCT01198392,Trial of S-1 Plus Cisplatin in Gastric Cancer,0.00233484588936265,0.0021846531345292236
NCT01100801,A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients,0.0020575336687629815,0.0018901482770938885
NCT01100814,Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer,0.0011440595264380965,0.0010475308421041272
NCT01106066,Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT,0.0016755753274682005,0.002118822574533309
NCT01179750,The Use of Ultrasonic Coagulating Shears Compared to Monopolar Electrocautery in Open Gastric Cancer Surgery,0.001342778499073678,0.0014567903920517994
NCT01138904,FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC),0.0016108320414475114,0.0017098961675293715
NCT01130337,A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer,0.0017229821691497717,0.0019437074543023683
NCT01160419,Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer,0.001708163965006899,0.0016989400652882478
NCT01197118,Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer,0.001564574485735362,0.0016307726294729284
NCT01133951,Helicobacter Pylori Eradication to Prevent Gastric Cancer,0.001540933781255391,0.0012675605679858253
NCT01152853,PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer,0.0020816224177573664,0.001890463101006658
NCT01123811,Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer,0.001380563897725266,0.001671067231168243
NCT01123473,"Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer",0.0015164737122380647,0.0015671122799017403
NCT01136031,Paclitaxel and Irinotecan in Advanced Gastric Cancer,0.001767188095450005,0.0018094413076937736
NCT01167049,Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis,0.0013229851053534985,0.0015044959831040097
NCT02071043,Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis,0.0018759782232524195,0.0015025428475370015
NCT02024438,Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer,0.001376852699877514,0.0012015526025363334
NCT02024841,Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis,0.0014387594641663822,0.0018369826921185086
NCT02015169,Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis,0.0016450378615433983,0.0018844216953509746
NCT02064803,Gastric Partitioning Procedure for the Treatment of Unresectable and Obstructive Distal Gastric Cancer,0.0012294710385256842,0.0014502389122445507
NCT02078362,ADCC Against Gastric Cancer Cells,0.002160383691034259,0.0011706732224787818
NCT02065765,International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer,0.0015246093824706978,0.0014342171897672822
NCT02004769,Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer,0.0015710560466791479,0.002059420278106716
NCT02008422,Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer,0.0016128307352094998,0.0017457109633110311
NCT02085031,Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric Cancer,0.0013716560850081975,0.0013266716182448984
NCT02005484,A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression,0.001991888138518474,0.0019256925161637568
NCT02092298,Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer,0.0013030260291469083,0.0014554729484842648
NCT02038621,The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer,0.001782367080377235,0.0020058779713636337
NCT02050659,Omentectomy in Radical Gastrectomy for Gastric Cancer Trial,0.0016114215633408343,0.0014856269018940656
NCT02007148,MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer,0.0022749851765681392,0.0014494230220012993
NCT02030561,NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer,0.0014087596142007264,0.0013713247211496833
NCT02090153,Study of S-1 Plus LV for Advanced Gastric Cancer,0.002483563305751775,0.0020643344339445363
NCT02072317,Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer,0.001540917895415974,0.002040796118355462
NCT02076594,Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer,0.0018444016036679104,0.0015426771809646017
NCT00983801,Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer,0.0015456687637549758,0.0020582218761589235
NCT00917384,Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma,0.001574525261739697,0.0015197007393981824
NCT00980603,Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer,0.001524675661632351,0.0019458217037568134
NCT00992199,Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer,0.001538636636937688,0.0016512178857973222
NCT00935779,Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer,0.001457779692827756,0.0012627544736982252
NCT00982592,Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer,0.0017106244852582492,0.002048006135151769
NCT00915382,Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer,0.0016603707466233113,0.0015580138328444646
NCT00978549,Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer,0.0014272263960331457,0.00121734166265579
NCT00976976,"Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer",0.0018786306731826774,0.002022599847881065
NCT00976768,"Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin",0.0015909750087324491,0.0018649012809747896
NCT00985192,Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer,0.001518143383631083,0.0013031428924936644
NCT00985556,"Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer",0.0016208052945256616,0.0016207332952555616
NCT00960349,Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients,0.0017422555964349475,0.0017159539119408608
NCT00911820,"Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer",0.001326204932578386,0.0016866205257146632
NCT00970138,Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer,0.0017929734096060752,0.001832043258841442
NCT00952497,A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer,0.0018182108801227507,0.001993724041561816
NCT00952003,Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients,0.0018562908211737258,0.002105288533268375
NCT00011960,Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery,0.0015844452005975248,0.0019027948317642727
NCT00017212,DX-8951f in Treating Patients With Metastatic Stomach Cancer,0.001789928687188995,0.0019149490963360576
NCT00017043,BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy,0.0017014790936639137,0.0019497736016469644
NCT00017056,BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy,0.0017014790936639137,0.0019497736016469644
NCT00006389,Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer,0.0015801793284395637,0.001937415878418262
NCT00006038,Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer,0.0018006961266500664,0.0021259134344789416
NCT00006081,Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer,0.0018617240608145198,0.0020839004813128148
NCT00087503,Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy,0.0018192872581362187,0.0018157591830007822
NCT00074009,Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma,0.0015052037920953673,0.001680609144236938
NCT00003524,Antineoplaston Therapy in Treating Patients With Stomach Cancer,0.0017561868043717125,0.0017327963398961707
NCT00003172,Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer,0.001751873452793352,0.0016925606108204227
NCT00003748,Irinotecan in Treating Patients With Esophageal or Stomach Cancer,0.00208033506378934,0.0020700713654111095
NCT00003137,Irinotecan in Treating Patients With Advanced Cancer of the Stomach,0.002108919256096432,0.0021890396238214613
NCT00003298,"Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer",0.0016560055642512,0.0019606983447531543
NCT00003055,Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer,0.001923655150783683,0.0021473193851151294
NCT00003862,Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer,0.0017939967109703793,0.001788646834561483
NCT00003192,Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus,0.0016546456789610375,0.0018822759491621658
NCT00062257,Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer,0.001789928687188995,0.001727715041362122
NCT00040859,Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer,0.0018351852696744343,0.0020716645137432545
NCT00048529,Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus,0.0019219574127071076,0.001868011848441535
NCT00045526,Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer,0.0018363767627420256,0.0013894941666276624
NCT00072787,Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer,0.002094277935013862,0.0022992422991355965
NCT00020826,Assessing Quality of Life of Patients With Stomach Cancer,0.0020424896026988767,0.0018077881802918412
NCT00068380,A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer,0.0015246093824706978,0.0013929322721198299
NCT00002783,Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer,0.0017464146454170186,0.002062682613961009
NCT00002615,Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer,0.0017464146454170186,0.0016423553063938086
NCT00002722,High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer,0.001949384912770457,0.002027886092584216
NCT00005060,Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer,0.0019156355101718084,0.0018571954686788807
NCT00005876,Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery,0.001828427495791055,0.0020991821490271454
NCT00005599,Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer,0.001804594071531992,0.002016658597768627
NCT00004099,Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer,0.0017464146454170186,0.0015603835667921421
NCT00004873,Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer,0.00209599528916434,0.001735502815762086
NCT00004257,Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer,0.0015616772724692397,0.001795601698050545
NCT00004236,Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer,0.0020726022070639083,0.002163163569003281
NCT00004103,Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer,0.0017464146454170186,0.001650240651294913
NCT00080002,Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction,0.0012004395562719053,0.0017089775588590686
NCT00054457,Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction,0.0015876179706220243,0.001984121068440342
NCT00054873,Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer,0.0015505393501454602,0.0017933963835477316
NCT00098527,FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer,0.0015256386399785827,0.0015532165560442027
NCT00032123,Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer,0.0017927867874370593,0.0020332313651377303
NCT01456598,Efficacy of Laparoscopic Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer,0.0015705403096207278,0.0014947282418703864
NCT01456455,Gastric Cancer Metastasized to the Central Nervous System (CNS),0.0012816090457945801,0.0008270203084449571
NCT01471132,Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis,0.0015673872105139413,0.0019050699216173945
NCT01471470,"Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer",0.0018522574929113816,0.0021746200786470875
NCT01406249,XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer,0.0018922110341630478,0.0031688596611888784
NCT01491217,A Study of Oraxol® in Gastric Cancer Patients,0.0019441797839881037,0.002182982499790503
NCT01482299,RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression,0.001519598108341227,0.0019480218331803473
NCT01426646,S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer,0.001707267251272873,0.0014745457118397795
NCT01441310,Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer,0.0013908328678907426,0.0013074299394533943
NCT01441336,Laparoscopic Gastrectomy for Advanced Gastric Cancer,0.0017995892840096952,0.002005507050342544
NCT01444755,The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric Cancer,0.0018709037252867245,0.0021890500105452393
NCT01444521,Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer,0.0017383788725757862,0.001947624080556942
NCT01402401,Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients,0.0015549003769509814,0.001998543200489113
NCT01416714,"Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy",0.001398936469106359,0.0014890235129838651
NCT01497964,Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy,0.001826548518448381,0.0016525443276402326
NCT01476553,Elimination of Peritoneal Tumor Cells With Extensive Peritoneal Lavage During Surgery in Patients With Gastric Cancer,0.0014212895717751264,0.0015695039677347039
NCT01401075,RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients,0.002182075298589867,0.0021180570635418667
NCT01490541,The Predictive Scores for Gastric Cancer in Gastric Intestinal Metaplasia (GIM) Patient: a Recommendation for Thai Population,0.001644546128467016,0.001596515855180396
NCT01461057,A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer,0.0020383594596501435,0.002228959705455288
NCT01283204,"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer",0.0015901739672853981,0.001802053016495921
NCT01283217,Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer,0.0012974678091184182,0.0015858030287597823
NCT01228045,A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer,0.0017578009002091944,0.0019781104137914134
NCT01212822,Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,0.0018031758344633144,0.002088313669145879
NCT01260194,A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer,0.0018184623734083967,0.001993048139565918
NCT01220934,An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer,0.0019186626747818602,0.0017218151091203582
NCT01219543,"A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.",0.0018971468052066383,0.001716168797157594
NCT01238055,Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer,0.001459596481903763,0.001842801771091986
NCT01227772,Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer,0.001995267089882409,0.001799078317114332
NCT01216644,"5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer",0.0018456251461178284,0.001963451493485632
NCT01262482,Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment,0.0015325523542233889,0.0016647759403541104
NCT01224652,Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy,0.0018098806369225354,0.001896156910488797
NCT01257711,A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer,0.0014085360253748302,0.0013967344453620478
NCT01206218,Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer,0.0018155121074256869,0.0025496579825138223
NCT01234324,ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction,0.0014495159644906776,0.001296121665919632
NCT01269255,A Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer,0.0018227522064147572,0.0017670167527975079
NCT01299688,HER2 Circulating Tumor Cells in Gastric Cancer,0.0021500169881542358,0.0011792226651008186
NCT02969148,Laparoscopic Bursectomy and D2 Lymphadenectomy vs.Laparoscopic D2 Lymphadenectomy in Advanced Gastric Cancer,0.0015651022458315423,0.0013959283887445232
NCT02951091,"Biomarker-Integrated Umbrella, Advanced Gastric Cancer",0.00210945586255219,0.0013132317656857277
NCT02902575,The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy,0.0016440151318369938,0.002082070665283965
NCT02903498,The Maintenance Treatment of UFT in Advanced Gastric Cancer,0.0022419040499458056,0.00227999615043809
NCT02931890,Multicentric Randomised Trial for Resectable Gastric Cancer,0.004083180949620297,0.001301858206161529
NCT02918162,Perioperative Chemo and Pembrolizumab in Gastric Cancer,0.001538797777984037,0.0013622564825104477
NCT02926716,NBI for Identifying Resection Margin Status in Gastric Cancer,0.0015362336715426994,0.0012580365408726385
NCT02901301,"Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer",0.0013072929610889591,0.0015687414008454502
NCT02949258,Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer,0.0012991672979850897,0.0016846378011216414
NCT02944539,Association Between Mitochondrial DNA Content and Risk of Gastric Cancer,0.0015362284228135328,0.001215658079217894
NCT02976142,The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer,0.0016173088493767007,0.001650499878146136
NCT02960061,Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer,0.001838179518509418,0.0017362728764302904
NCT02995850,"A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis",0.001459773421843319,0.0013532147474621167
NCT02942329,Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer,0.0016967045117915512,0.00140804800235758
NCT02935634,A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer,0.0020228965255435875,0.001976497736326995
NCT02500043,Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer,0.001720571268302368,0.0016908962658204775
NCT02583659,The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study,0.0017860473690008726,0.0022657835701183895
NCT02594943,Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer,0.0011590923776299011,0.0014438031199508667
NCT02563054,A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer,0.0018379461608712562,0.0017729294058004038
NCT02560974,A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer,0.0014460403356669014,0.0014547674787393097
NCT02555358,Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study,0.0017491667456740248,0.0019851785119145036
NCT02541461,Body Composition After Laparoscopic Gastrectomy for Gastric Cancer,0.0013681567086106443,0.0013496916929265008
NCT02518529,Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients,0.0016144755392069777,0.0015359404089688449
NCT02577263,Impact of Adjuvant FOLFOX on Quality of Life and Sensory Neurotoxicity in Patients With Advanced Gastric Cancer,0.0017168825406701142,0.0016536334533984696
NCT02596256,Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301),0.0016938380231088816,0.0023257162759328606
NCT02510469,Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells,0.001153887469880172,0.0015089220085468449
NCT02537171,Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer,0.0015668599045714079,0.0017768725293924505
NCT02521649,Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer,0.001627453288887558,0.0015915258549712992
NCT02514551,A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer,0.0016765298136685234,0.0017140991640759984
NCT02528110,Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer,0.0017536494834441356,0.0013151332480742703
NCT02509806,Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer,0.0012388664530203954,0.0018773583680505642
NCT02585908,Safety and Efficacy of γδ T Cell Against Gastric Cancer,0.002167125559975479,0.002752079864741911
NCT02527785,"Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer",0.001672963318350461,0.002462651844916144
NCT02529878,Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer,0.0015531471749314811,0.0017634938089252012
NCT02525237,Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer,0.001795455744902998,0.001935933230688485
NCT02501603,"Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer",0.0015568538128773646,0.0012337705831370332
NCT00687843,Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients,0.0019441797839881037,0.001787094605526452
NCT00663741,Sorafenib Gastric Cancer Asian Phase I Study,0.0019264253721345637,0.0016025217078485226
NCT00673673,FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer,0.001323930495761261,0.0015993795403152352
NCT00606619,Effects of Early Oral Feeding After Resection of Gastric Cancer,0.0015477302762821712,0.0015339906043575725
NCT00611507,A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer,0.001895303949768609,0.0019611129828598375
NCT00683787,Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer,0.0015240138186159852,0.0015461543981493168
NCT00681577,Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer,0.0014678078419169405,0.0018007932246787025
NCT00681252,Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer,0.0014678078419169405,0.0018007932246787025
NCT00669370,Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer,0.0018299450900241215,0.001999157973608608
NCT00635596,"Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer",0.001297477076863554,0.0011676992772888183
NCT00639327,Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer,0.001853270672896436,0.001763035398669322
NCT00675194,Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer,0.0016410225084449947,0.0018517279328520739
NCT00699881,Study of Cetuximab to Treat Gastric Cancer,0.0019445768383752173,0.00288656192400041
NCT00601510,"Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer",0.0015913474942350874,0.001592925098911478
NCT00661167,Phase II Study of ABI-007 for Gastric Cancer,0.002722476534486823,0.0015665176220035582
NCT00629863,Endoscopic Ultrasound in Diagnosing Cancer in Patients With Localized Stomach Cancer or Esophageal Cancer,0.0014026276458288657,0.001112570396799351
NCT00632268,Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer,0.0016977831276247793,0.001983720203177568
NCT00680901,"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib",0.0014330736030762604,0.0019148491688203957
NCT00335959,"S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery",0.0015524510592072047,0.0014808388009183177
NCT00382720,Docetaxel and Oxaliplatin in Gastric Cancer,0.0017224690004001514,0.001756530844589719
NCT00398398,Study of XELOX With Cetuximab in Advanced Gastric Cancer,0.0020127940031317384,0.0017523360413153643
NCT00343668,S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer,0.0017518854954486373,0.001638246801380268
NCT00374036,Metastatic Gastric Cancer FFCD 03-07,0.002431217704575302,0.0015598389605171248
NCT00375999,Docetaxel and Epirubicin in Advanced Gastric Cancer,0.001773837797696158,0.0016429042843996101
NCT00384878,Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric Cancer,0.0017906571588112593,0.002067571849587521
NCT00397904,"Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin",0.001582253613190747,0.0015260668853965367
NCT00394433,"Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer",0.0013624409653334624,0.0018211600530898366
NCT00313872,Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer,0.0012998138743577504,0.0014409495013989993
NCT00359476,A Study of Vinflunine in Patients With Gastric Cancer,0.0019441797839881037,0.0018080425379759946
NCT00320515,Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer,0.0018483480425521062,0.001721141908343039
NCT00320294,ILF With/Without Cisplatin for Advanced Gastric Cancer,0.002221937538320067,0.0017196248918236537
NCT00354224,"Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer",0.0018980965442839004,0.001809336675024073
NCT00741676,Comparison of the Laparoscopy-Assisted Distal Gastrectomy and Open Distal Gastrectomy for Advanced Gastric Cancer,0.001534038781907105,0.001226045523773499
NCT00711243,"Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor",0.0016072296804445557,0.0016273372446073272
NCT00746161,Evaluation of Double Tract Reconstruction After Total Gastrectomy in Patients With Gastric Cancer,0.0014392735705317998,0.0016553805653493389
NCT00725712,Study of GSK1363089 in Metastatic Gastric Cancer,0.0021159773767876924,0.0017990802090921394
NCT00738478,Quality of Life After Routine Nasogastric Decompression After Distal Gastrectomy for Gastric Cancer Patients,0.001403822879316473,0.0015198274534400098
NCT00735566,Antiangiogenic Factors in Gastric Cancer,0.0021434158499589236,0.0014862739229452475
NCT00757640,Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery,0.0012590269327878698,0.001097324973539631
NCT00718913,Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer,0.0014125286303414005,0.0016845905491538744
NCT00743964,"Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)",0.0017971939869356993,0.0017266111137236543
NCT00729482,RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment,0.0015170809914872385,0.0020269378036362616
NCT00407186,Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS),0.0013431723334362783,0.001933749309703908
NCT00477880,Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer,0.0014765458255217069,0.0010881707045317665
NCT00477711,A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer,0.0018356595509478062,0.0019014300755687003
NCT00464893,Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection,0.0016441725705826791,0.001967626839878185
NCT00420394,Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer,0.0021804085679114618,0.0014302254512742164
NCT00400179,A Safety and Efficacy Study in Patients With Gastric Cancer,0.002423734554395834,0.0016522831116944341
NCT00446290,"Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer",0.001826049200365542,0.0017018647608454422
NCT00429078,Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer,0.002160383691034259,0.00136370128162305
NCT00415168,Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer,0.0011738892262893842,0.0015841957452940175
NCT00452751,Comparison of Laparoscopic Versus Open Gastrectomy for Gastric Cancer: A Prospective Randomized Trial,0.0012612677763564617,0.0017790589306109165
NCT00439608,"BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer",0.0011496386499452132,0.0011918272871543588
NCT00414271,Neo-Adjuvant Chemotherapy in Locally Advanced Gastric Cancer,0.0021401809005568415,0.0022013013657916484
NCT00436241,A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.,0.002138373358977871,0.002066827464291045
NCT00447746,A Comparison Between D1 and D2 Lymphadenectomy in Gastric Cancer : A Prospective Randomized Controlled Trial,0.0013102928658378984,0.0013531672118594978
NCT00411151,Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer,0.0017389788268759063,0.0017028062506835573
NCT00411229,Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer,0.001721607394646174,0.001675373886979284
NCT00454636,A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.,0.002169344597412445,0.002087690047141781
NCT00498134,Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase Pathway,0.0012790411230661517,0.0015404841963123693
NCT00486954,Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer,0.0017441888939281425,0.001914073367292936
NCT01824004,Postoperative Chemoradiotherapy With S-1 in Gastric Cancer,0.0021804085679114618,0.0023158752141624697
NCT01848015,Circulating Tumor Cells (CTCs) in Advanced Gastric Cancer,0.0020987256947725963,0.0013505459927189985
NCT01874938,"A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer",0.001995267089882409,0.001803936238514293
NCT01830907,Efficacy of Preoperative Nutritional Support on Postoperative Outcome in Gastric Cancer Patients at Nutritional Risk by NRS-2002,0.0016428779586631507,0.0015163575261191737
NCT01830270,"Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer",0.0014816006572286244,0.002164509897721371
NCT01815853,Pre-operative Chemoradiotherapy or Chemotherapy Following Surgery and Adjuvent Chemotherapy in Patients With Gastric Cancer,0.0016660767063764583,0.0017669352253047463
NCT01836991,D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer,0.0016923932074337593,0.0024147015816715794
NCT01836120,A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer,0.0015778421091490731,0.0017997019946368903
NCT01814345,Her 2 Testing in Indian Patients With Gastric Cancer,0.0028945006327693113,0.0018057237383445768
NCT01813994,Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer,0.0013550048480113978,0.001646785991624815
NCT01889303,Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer,0.0017939360469721674,0.0018089794532649664
NCT01847794,HER2 Positive CTC in Advanced Gastric Cancer,0.002104522585784839,0.001249961640787858
NCT01839500,EVIDENCE: A Non-Interventional Study of Treatment and Clinical Outcomes in Chinese Patients With Gastric Cancer,0.0017219411437088025,0.0017870267283157334
NCT01876927,Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer,0.0020844882223357286,0.0020749261583888614
NCT01854255,Intraperitoneal Aerosol Chemotherapy in Gastric Cancer,0.0024111686619753612,0.0016384391071845347
NCT01851941,"A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer",0.0019032897945744356,0.0019626171231441475
NCT01980407,"Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer",0.001724691285030455,0.0016921785546912269
NCT01967875,A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer,0.0017803281412027657,0.0017999668170411074
NCT01919242,Postoperative Morbidity and Mortality After Gastrectomy for Gastric Cancer: Prospective Cohort Study,0.0016230472685756648,0.0012203381190441273
NCT01921673,Dovitinib Plus Docetaxel in Gastric Cancer,0.001630171850409284,0.0010999301330374275
NCT01924533,Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.,0.0017385872041802842,0.001825300023641518
NCT01914692,Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection,0.0015258181205749786,0.001423518664705188
NCT01956149,Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer,0.0020550328659665828,0.001962548015892065
NCT01927146,Lauren Classifications and HER2 Status in Gastric Cancer Patients,0.0016451077529117742,0.0017360752247024232
NCT01928524,Chemotherapy for Patients With Cancer of the Stomach,0.002215156425212201,0.0021929108602434205
NCT01946061,A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer,0.0018046810717710431,0.0017021205594343611
NCT01962376,Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis,0.001282912827949196,0.0011860335273858322
NCT01910948,Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients,0.001642861190584455,0.0011548330594967958
NCT01955096,Fast Track Surgery With Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer: a Randomized Controlled Trial,0.0015366009031281243,0.0019975399340322157
NCT01935778,Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV,0.0015384465592861033,0.0015370757679083907
NCT01961791,Lymph Node Staging System With a Novel Concept for Gastric Cancer: a Hybrid Type of Topographic and Numeric Ones,0.0011408965203712847,0.000788621458672849
NCT01971775,Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer,0.0013802456413618844,0.0013040925518871711
NCT01905969,Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy,0.0013148080182050484,0.0014637755861654246
NCT01964027,The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer,0.001802682859225085,0.002034309130100474
NCT01978444,Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）for Advanced Gastric Cancer,0.001710734906362144,0.0015340536902310057
NCT01939275,64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer,0.0016780794499565942,0.0015516401790436737
NCT02641925,Omentectomy for Metabolic Syndrome in Gastric Cancer Patients,0.0016468092859869103,0.001052387261853983
NCT02649348,Effects of Preoperative Exercise in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome,0.0016445540385281881,0.001184423166075214
NCT02686424,Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy (ONCO-RD 010 CRT),0.001421587117260773,0.0016626934154071289
NCT02623153,"Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer",0.0013453475120605931,0.001664904001266385
NCT02672865,Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer,0.0020954479724340285,0.0015403415315507496
NCT02624271,Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk,0.001350347844303622,0.0010137569765044936
NCT02647476,Postoperative Enteral Immunonutrition in Gastric Cancer,0.004083180949620297,0.0012606975290188015
NCT02663427,Serological Screening of Gastric Cancer in Wuxi Region,0.0021469058911950745,0.0012238892346978377
NCT02610218,Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer,0.0015765514039780895,0.00151806395089951
NCT02640898,Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer,0.0013381216709138217,0.0012620911521252318
NCT02625610,Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),0.0012953086475586937,0.0020516446062898387
NCT02625623,Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),0.0012953086475586937,0.0015330491627402023
NCT02632201,Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis,0.001493635956329667,0.0016109116864994949
NCT02604784,"Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors",0.0017003022170932215,0.0016119429007373713
NCT02668380,"An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer",0.0018301718025092028,0.0019030382342902822
NCT02697838,Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer,0.0017795140515575684,0.0018093953084559523
NCT02648841,A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.,0.0019245084022004783,0.001833614955017261
NCT02662959,Irinotecan as 3rd Line Therapy in Gastric Cancer,0.0014321766559942089,0.0015464948469732028
